Assessing the impact of lighting on multiple myeloma patients undergoing stem cell transplantation
Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever and Symptom Burden Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
This study is testing if better lighting in hospital rooms can help multiple myeloma patients feel better and recover more effectively during their stem cell transplant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Trial ID | NCT05737732 on ClinicalTrials.gov |
What this trial studies
This multi-site randomized control trial aims to evaluate how systematic lighting affects circadian rhythm, inflammation, neutropenic fever, and symptom burden in multiple myeloma patients undergoing autologous stem cell transplantation. A total of 200 participants will be assigned to receive either circadian-effective or circadian-ineffective lighting in their hospital rooms. Over a 2-month period, the study will measure sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels, and overall symptom burden. The goal is to determine if improved lighting can enhance patient outcomes during a critical treatment phase.
Who should consider this trial
Good fit: Ideal candidates are adults aged 21 and older with a diagnosis of multiple myeloma scheduled for their first autologous stem cell transplant.
Not a fit: Patients with previous stem cell transplants, severe psychological impairments, or active infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved sleep quality and reduced complications for multiple myeloma patients undergoing stem cell transplantation.
How similar studies have performed: While the specific approach of using lighting for circadian rhythm alignment in this context is novel, similar studies have shown promising results in other patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multiple Myeloma diagnosis * Scheduled to undergo their first Autologous Stem Cell Transplant procedure. * 21years or older * Able to provide informed consent. * English-language proficient Exclusion Criteria: * Previous Autologous Stem Cell Transplant procedure * Pregnancy * Eye diseases which limit the ability of light to be processed * Secondary cancer diagnosis within the last 5 years * Severe sleep disorders * History of bipolar disorder or manic episodes * Severe psychological impairment * Previous use of light therapy * Active infection including COVID-19 infection
Where this trial is running
New York, New York and 1 other locations
- Icahn Schoool of Medicine at Mount Sinai — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Mariana Figueiro, PhD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Barbara Plitnick, BSN
- Email: Barbara.Plitnick@mountsinai.org
- Phone: 518 242-4603
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.